May 2021
  • Mergers & acquisitions

Founded in 2007 and located in Martillac (33), IMPLANET is a medical technology company manufacturing premium implants for orthopaedic surgery.

Its activity is organized around two product ranges, (i) the latest generation JAZZ® implant dedicated to the treatment of spinal pathologies involving spinal fusion and (ii) the MADISON® total knee prosthesis. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the FDA in the United States, CE marking in Europe and ANVISA clearance in Brazil.

Relying on a team of 29 employees, IMPLANET has two subsidiaries in the United States and Germany, and achieved a turnover of €6m in 2020.

OSD, based in Avignon (84) since 2007, benefits from (i) a complete range of implants dedicated to spine surgery and (ii) a strong direct positioning on the French market. OSD, with a complete range already CE certified, recently obtained 510(k) regulatory clearance from the FDA in the United States. The merger, motivated by numerous, product, regulatory and commercial synergies, will allow the emergence of a new key player in the orthopaedic and spine market in France and internationally.

ATOUT CAPITAL advised IMPLANET in its strategic thinking upstream and throughout the acquisition process, from the identification of potential targets to the initiation of negotiations and the structuring of the transaction.

This acquisition constitutes a new milestone in the strategy, implemented since the end of 2019, to strengthen IMPLANET’s presence in the spine market. It will also enable the new entity to rapidly reach the critical size in order to meet the regulatory, clinical and economic requirements in the fast-growing spine market, for the coming years.

Can we help you?
In both public and private companies, Atout Capital is able
to provide a unique transversal expertise with a 360 degree approach.